Market Overview:
The global epigenetics diagnostic market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of cancer, technological advancements in epigenetics diagnostics, and growing demand for personalized medicine. The global epigenetics diagnostic market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into reagents, kits, instruments, enzymes and services. The reagents segment is expected to account for the largest share of the global epigenetics diagnostic market in 2018 owing to its wide applicability in various types of assays such as PCR-based assays and methylation-specific PCR (MSP). Oncology applications are expected to account for a larger share of the global epigenetics diagnostic market than non-oncology applications duringthe forecast period owingto rising incidencesof cancer worldwide.
Product Definition:
Epigenetics is the study of changes in gene expression that are not caused by changes in the DNA sequence. Epigenetics Diagnostic is a laboratory test used to determine whether a change in gene expression is due to epigenetic modifications. The importance of epigenetics diagnostics lies in its ability to identify environmental factors that may be contributing to disease.
Reagents:
Reagents are chemicals that help in detecting or measuring a particular substance. Reagents come in different forms such as liquids, powders, and gases. These reagents when introduced into the body fluids or tissue of patients give accurate results regarding to the presence of a disease gene or mutation.
The global reagent market is expected to witness significant growth over the forecast period owing to increasing demand for diagnostics tests across various healthcare settings especially hospitals.
Kits:
Kits are small test tubes or containers that contain reagents and enzymes. Kits are used for detecting the presence of epigenetic modifications in a specific biological sample. Epigenetic modifications include DNA methylation, histone methylation, and chromatin structures like nucleosomes which affect gene expression without changing the sequence of DNA.
Application Insights:
Oncology dominated the global market in terms of revenue share in 2017. Epigenetic modifications are known to be involved in the etiology of cancers and a number of studies have indicated that these modifications can be used as biomarkers for cancer detection. This has led to an increased demand for epi-diagnostics for oncology, which is expected to drive growth over the forecast period.
Non-oncology applications include epigenetic changes related to diabetes, cardiovascular diseases, respiratory disorders and infectious diseases. These applications collectively accounted for revenue share in 2018 of around 40% among other segments such as endocrinology and metabolic disease management.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, availability of advanced technologies and high adoption rate for these products. The region is expected to maintain its dominance throughout the forecast period owing to constant developments undertaken by companies operating within it.
Asia Pacific is anticipated to witness lucrative growth over the coming years due to rising incidences of various cancers among people in Asian countries such as India, China and Japan. EpiGen Research Consortium based at Imperial College London has carried out research studies on epigenetic base diseases prevalent among Asian population which includes diabetes, obesity, cardiovascular diseases (CVDs), inflammatory bowel disease (IBD) and cancer amongst others.- Diabetic retinopathy affects more than 1 billion individuals worldwide accounting for around 60% blindness cases globally- IBD affecting nearly 3 million people in U.S.
Growth Factors:
- Increasing incidence of cancer and other diseases that can be treated with epigenetic drugs
- Growing demand for personalized medicine
- Advances in technology that make it easier to study epigenetics
- Increased funding for epigenetics research
- More pharmaceutical companies investing in epigenetic drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Epigenetics Diagnostic Market Research Report
By Type
Reagents, Kits, Instruments, Enzymes, Services
By Application
Oncolog, Non-oncology
By Companies
Roche Diagnostics, Thermo Fisher Scientific, Inc., Eisai Co. Ltd., Novartis AG, Illumina, Inc., Merck, Qiagen, Abcam plc, Diagenode Diagnostics, Active Motif, Zymo Research Corporation, CellCentric, Valirx
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
171
Number of Tables & Figures
120
Customization Available
Yes, the report can be customized as per your need.
Global Epigenetics Diagnostic Market Report Segments:
The global Epigenetics Diagnostic market is segmented on the basis of:
Types
Reagents, Kits, Instruments, Enzymes, Services
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncolog, Non-oncology
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche Diagnostics
- Thermo Fisher Scientific, Inc.
- Eisai Co. Ltd.
- Novartis AG
- Illumina, Inc.
- Merck
- Qiagen
- Abcam plc
- Diagenode Diagnostics
- Active Motif
- Zymo Research Corporation
- CellCentric
- Valirx
Highlights of The Epigenetics Diagnostic Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Reagents
- Kits
- Instruments
- Enzymes
- Services
- By Application:
- Oncolog
- Non-oncology
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Epigenetics Diagnostic Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Epigenetics is the study of heritable changes in gene expression that do not involve a change in the DNA sequence. Epigenetic changes can be caused by environmental factors, such as exposure to toxins or radiation, or by genetic factors. Epigenetic diagnostic tests are used to identify epigenetic changes associated with diseases and conditions.
Some of the major companies in the epigenetics diagnostic market are Roche Diagnostics, Thermo Fisher Scientific, Inc., Eisai Co. Ltd., Novartis AG, Illumina, Inc., Merck, Qiagen, Abcam plc, Diagenode Diagnostics, Active Motif, Zymo Research Corporation, CellCentric, Valirx.
The epigenetics diagnostic market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Epigenetics Diagnostic Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Epigenetics Diagnostic Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Epigenetics Diagnostic Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Epigenetics Diagnostic Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Epigenetics Diagnostic Market Size & Forecast, 2018-2028
4.5.1 Epigenetics Diagnostic Market Size and Y-o-Y Growth
4.5.2 Epigenetics Diagnostic Market Absolute $ Opportunity
Chapter 5 Global Epigenetics Diagnostic Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Epigenetics Diagnostic Market Size Forecast by Type
5.2.1 Reagents
5.2.2 Kits
5.2.3 Instruments
5.2.4 Enzymes
5.2.5 Services
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Epigenetics Diagnostic Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Epigenetics Diagnostic Market Size Forecast by Applications
6.2.1 Oncolog
6.2.2 Non-oncology
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Epigenetics Diagnostic Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Epigenetics Diagnostic Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Epigenetics Diagnostic Analysis and Forecast
9.1 Introduction
9.2 North America Epigenetics Diagnostic Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Epigenetics Diagnostic Market Size Forecast by Type
9.6.1 Reagents
9.6.2 Kits
9.6.3 Instruments
9.6.4 Enzymes
9.6.5 Services
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Epigenetics Diagnostic Market Size Forecast by Applications
9.10.1 Oncolog
9.10.2 Non-oncology
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Epigenetics Diagnostic Analysis and Forecast
10.1 Introduction
10.2 Europe Epigenetics Diagnostic Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Epigenetics Diagnostic Market Size Forecast by Type
10.6.1 Reagents
10.6.2 Kits
10.6.3 Instruments
10.6.4 Enzymes
10.6.5 Services
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Epigenetics Diagnostic Market Size Forecast by Applications
10.10.1 Oncolog
10.10.2 Non-oncology
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Epigenetics Diagnostic Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Epigenetics Diagnostic Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Epigenetics Diagnostic Market Size Forecast by Type
11.6.1 Reagents
11.6.2 Kits
11.6.3 Instruments
11.6.4 Enzymes
11.6.5 Services
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Epigenetics Diagnostic Market Size Forecast by Applications
11.10.1 Oncolog
11.10.2 Non-oncology
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Epigenetics Diagnostic Analysis and Forecast
12.1 Introduction
12.2 Latin America Epigenetics Diagnostic Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Epigenetics Diagnostic Market Size Forecast by Type
12.6.1 Reagents
12.6.2 Kits
12.6.3 Instruments
12.6.4 Enzymes
12.6.5 Services
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Epigenetics Diagnostic Market Size Forecast by Applications
12.10.1 Oncolog
12.10.2 Non-oncology
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Epigenetics Diagnostic Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Epigenetics Diagnostic Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Epigenetics Diagnostic Market Size Forecast by Type
13.6.1 Reagents
13.6.2 Kits
13.6.3 Instruments
13.6.4 Enzymes
13.6.5 Services
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Epigenetics Diagnostic Market Size Forecast by Applications
13.10.1 Oncolog
13.10.2 Non-oncology
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Epigenetics Diagnostic Market: Competitive Dashboard
14.2 Global Epigenetics Diagnostic Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche Diagnostics
14.3.2 Thermo Fisher Scientific, Inc.
14.3.3 Eisai Co. Ltd.
14.3.4 Novartis AG
14.3.5 Illumina, Inc.
14.3.6 Merck
14.3.7 Qiagen
14.3.8 Abcam plc
14.3.9 Diagenode Diagnostics
14.3.10 Active Motif
14.3.11 Zymo Research Corporation
14.3.12 CellCentric
14.3.13 Valirx
